title: Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.
abstract: Recombinant adeno-associated virus (rAAV) vectors offer promise for gene therapy of alpha-1 antitrypsin (AAT) deficiency. A toxicology study in mice evaluated intramuscular injection of an rAAV vector expressing human AAT (rAAV-CB-hAAT) produced using a herpes simplex virus (HSV) complementation system or a plasmid transfection (TFX) method at doses of 3 × 10(11) vg (1.2 × 10(13) vg/kg) for both vectors and 2 × 10(12) vg (8 × 10(13) vg/kg) for the HSV-produced vector. The HSV-produced vector had favorable in vitro characteristics in terms of purity, efficiency of transduction, and hAAT expression. There were no significant differences in clinical findings or hematology and clinical chemistry values between test article and control groups and no gross pathology findings. Histopathological examination demonstrated minimal to mild changes in skeletal muscle at the injection site, consisting of focal chronic interstitial inflammation and muscle degeneration, regeneration, and vacuolization, in vector-injected animals. At the 3 × 10(11) vg dose, serum hAAT levels were higher with the HSV-produced vector than with the TFX-produced vector. With the higher dose of HSV-produced vector, the increase in serum hAAT levels was dose-proportional in females and greater than dose-proportional in males. Vector copy numbers in blood were highest 24 hr after dosing and declined thereafter, with no detectable copies present 90 days after dosing. Antibodies to hAAT were detected in almost all vector-treated animals, and antibodies to HSV were detected in most animals that received the highest vector dose. These results support continued development of rAAV-CB-hAAT for treatment of AAT deficiency.
authors.affiliation: Applied Genetic Technologies Corporation, 11801 Research Drive, Alachua, FL 32615, USA. jchulay@agtc.com
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Chulay
authors.forename: Guo-Jie
authors.initials: GJ
authors.lastname: Ye
authors.forename: Darby L
authors.initials: DL
authors.lastname: Thomas
authors.forename: David R
authors.initials: DR
authors.lastname: Knop
authors.forename: Janet M
authors.initials: JM
authors.lastname: Benson
authors.forename: Julie A
authors.initials: JA
authors.lastname: Hutt
authors.forename: Gensheng
authors.initials: G
authors.lastname: Wang
authors.forename: Margaret
authors.initials: M
authors.lastname: Humphries
authors.forename: Terence R
authors.initials: TR
authors.lastname: Flotte
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D002478:Cells, Cultured; D000229:Dependovirus / Q000235:genetics*; D004353:Drug Evaluation, Preclinical; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000097:blood / Q000378:metabolism*; D057809:HEK293 Cells; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000378:metabolism; D010957:Plasmids / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics*; D014162:Transfection; D000515:alpha 1-Antitrypsin / Q000235:genetics*; D019896:alpha 1-Antitrypsin Deficiency / Q000628:therapy*
chemical_list: D000515:alpha 1-Antitrypsin
references.citation: J Virol. 1999 May;73(5):3994-4003
references.pmid: 10196295
references.citation: Gene Ther. 2004 Jul;11(13):1081-6
references.pmid: 15057263
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8
references.pmid: 19706466
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9
references.pmid: 12192090
references.citation: Gene Ther. 2001 Sep;8(17):1299-306
references.pmid: 11571566
references.citation: Percept Psychophys. 2001 Nov;63(8):1399-420
references.pmid: 11800465
references.citation: Bioinformatics. 2003 May 22;19(8):966-72
references.pmid: 12761059
references.citation: Gene Ther. 2009 Feb;16(2):229-39
references.pmid: 18923452
references.citation: Blood. 2003 Jul 15;102(2):480-8
references.pmid: 12637328
references.citation: Hum Gene Ther. 1998 Dec 10;9(18):2745-60
references.pmid: 9874273
references.citation: N Engl J Med. 2002 Nov 21;347(21):1652-61
references.pmid: 12444179
references.citation: Mol Ther. 2009 Jan;17(1):81-7
references.pmid: 18941444
references.citation: J Gene Med. 2006 Jun;8(6):730-5
references.pmid: 16518879
references.citation: J Gene Med. 2005 Jul;7(7):842-50
references.pmid: 15838934
references.citation: Blood. 2003 Apr 15;101(8):2963-72
references.pmid: 12515715
references.citation: Chest. 1991 Sep;100(3):703-8
references.pmid: 1889260
references.citation: J Virol. 2003 Feb;77(4):2768-74
references.pmid: 12552020
references.citation: JAMA. 2006 Aug 23;296(8):964-73
references.pmid: 16926356
references.citation: JAMA. 1999 Jul 28;282(4):331-40
references.pmid: 10432030
references.citation: J Virol. 2002 Jan;76(2):791-801
references.pmid: 11752169
references.citation: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14384-8
references.pmid: 9826709
references.citation: N Engl J Med. 2009 Jun 25;360(26):2749-57
references.pmid: 19553648
references.citation: Chest. 1989 Jan;95(1):196-208
references.pmid: 2642408
references.citation: Hum Gene Ther. 2007 Mar;18(3):245-56
references.pmid: 17376008
references.citation: Clin Infect Dis. 2005 May 1;40(9):1271-81
references.pmid: 15825029
references.citation: Hum Gene Ther. 2006 Dec;17(12):1177-86
references.pmid: 17115945
references.citation: Mol Ther. 2001 Sep;4(3):217-22
references.pmid: 11545612
references.citation: Nat Med. 2006 Mar;12(3):342-7
references.pmid: 16474400
references.citation: Hum Gene Ther. 2009 Aug;20(8):861-70
references.pmid: 19419276